MARKET WIRETradingView • 13h ago
CapsoVision, Inc. Estimates – NASDAQ:CVTradingView report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
Why CV Stock slipped -1.58% Today — RQD Quant Desk Flash
$6.83 -1.58% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $6.80
CapsoVision Inc. (CV) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $369.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CV Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, CapsoVision Inc. (NASDAQ: CV) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $6.83 (-1.58% 1D, market cap $369.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CV ranks #409 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CV compare to ELMD and FOCL in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), CV carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 52.9%, and ROIC of -35.0%. By comparison, ELMD (Electromed Inc.) holds a C grade (65/100 RQD, P/E 30.4x, ROIC 24.1%, cap $229.4M) and FOCL (EDAP TMS S.A.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $191.6M). Among the 5-stock peer group, ELMD leads on earnings multiple (30.4x) while ELMD leads on capital efficiency (24.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CV?
▼
Per CV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001378325), CapsoVision Inc. generated $13.6M in revenue (+15.3% YoY), -$25.3M in net income, and -$23.0M in free cash flow against $18.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $6.80 (-0.47%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-5.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CV)Realized 20D OHLCV Swing Band: ±8.6%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY CV SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (31% of score)
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (22% of score)
20D Institutional Volume Accumulation (±8.6% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$6.76-1.3% Next Q
37
Q2 (-2Q)Grade D$6.67+3.3% Next Q
40
Q3 (-1Q)Grade D$6.89-0.9% Next Q
42
CurrentGrade D$6.83-6.3% Hist 90D α
45
Trajectory: E (37) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CV Turnaround Squeeze
While CV currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.44) and Max Pain ($7.17) forces dealer call-delta covering toward $16.14.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CV• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CV Stock slipped -1.58% Today — RQD Quant Desk Flash
CapsoVision Inc. (CV) slipped -1.58% to $6.83, trading at 21% of its 52-week range ($4.5 – $15.37). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 21% of its 52-week range ($4.5 – $15.37) with RSI-14 at 56.5 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.6% around $6.83 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52.9% gross margin and $0 annual free cash flow.
Live CV Headlines & Catalysts
MARKET WIREYahoo Finance • 16h ago
CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026Yahoo Finance report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 19h ago
A live webcast will cover CapsoVision's results and corporate update on Nov. 12.Stock Titan report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 22h ago
CapsoVision to Present at the 20th Annual LD Micro Main EventYahoo Finance report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
CapsoVision Inc. (CV) Edges Higher to $6.53 as Buyers Test Upper Range - Wyckoff Distributionhttps://www.siam.in/ report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com UK • 1d ago
CapsoVision at ld micro main event: capsule platform targets cancer screeningInvesting.com UK report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 1d ago
CapsoVision Inc. (CV) Holds Near $6.68 as Traders Eye $7.01 Resistance - Box Spreadhttps://www.dars.gov.et/ report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.siam.in/ • 1d ago
CapsoVision (CV) Climbs 6.73% to $6.58 as Buyers Push Toward Key Resistance - Growth Factorhttps://www.siam.in/ report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 9d ago
CapsoVision Maps AI Capsule Push Into Colon, Pancreatic Cancer ScreeningCapsoVision (NASDAQ:CV) outlined its strategy to expand capsule endoscopy technology beyond its current small-bowel business into colon, pancreatic and esophageal cancer screening applications, highlighting its artificia
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CV)
- ✓Walkthrough of CV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -3.39%▲ ASCENDING TRIANGLE
2026-11-02O $7.06H $7.06L $6.83C $6.83VOL 102.0K
RES: $7.23SUP: $5.91SMA50: $6.44SMA200: $6.36
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +15.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CV today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CV. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CV)
Health Care Rank #409 of 1016
⚔️ ELMD vs CV Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CV vs. ELMD, FOCL, INMD, HSDT)
Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, CapsoVision Inc. (CV) ranks #409 by composite RQD confidence (45/100, grade D) and #493 by equity capitalization ($369.2M). Within this direct 5-issuer industry benchmark cohort, ELMD leads on earnings valuation at 30.4x trailing P/E, while ELMD leads on capital efficiency and profitability with 24.1% ROIC and 78.1% gross margin. ELMD currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with CV at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CV
ACTIVE
CapsoVision Inc. | D | 45/100 | — | 52.9% | -35.0% | -1.58% | $369.2M | Benchmark Subject |
| ELMD Electromed Inc. | C | 65/100 | 30.4x | 78.1% | 24.1% | -2.31% | $229.4M | /elmd-vs-cv → |
| FOCL EDAP TMS S.A. | E | 28/100 | — | 42.5% | -35.0% | +0.24% | $191.6M | /focl-vs-cv → |
| INMD InMode Ltd. | D+ | 58/100 | — | 78.5% | 17.7% | -2.15% | $776.6M | /inmd-vs-cv → |
| HSDT Solana Company (Class A) | D- | 38/100 | — | 96.0% | -35.0% | -7.52% | $146.5M | /hsdt-vs-cv → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001378325In its most recent audited fiscal period (FY2025, filed 2025-12-31), CapsoVision Inc. (CV) reported GAAP revenue of $13.6M (+15.3% vs. FY2024 revenue of $11.8M ) , GAAP net income of -$25.3M, operating cash flow of -$22.9M, and free cash flow of -$23.0M (-13.4% YoY). On the balance sheet, CV closed FY2025 with $18.2M in total assets against $0 in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $13.6M | -$25.3M | -$22.9M | -$23.0M | $18.2M | — |
| FY2024 (FY) | 2024-12-31 | $11.8M | -$19.9M | -$20.1M | -$20.2M | $16.8M | — |
3. CV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, CapsoVision Inc. (NASDAQ: CV) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $6.83 (-1.58% 1D, market cap $369.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CV ranks #409 in composite RQD confidence.
How does CV compare to ELMD and FOCL in the Health Care sector?
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), CV carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 52.9%, and ROIC of -35.0%. By comparison, ELMD (Electromed Inc.) holds a C grade (65/100 RQD, P/E 30.4x, ROIC 24.1%, cap $229.4M) and FOCL (EDAP TMS S.A.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $191.6M). Among the 5-stock peer group, ELMD leads on earnings multiple (30.4x) while ELMD leads on capital efficiency (24.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CV?
Per CV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001378325), CapsoVision Inc. generated $13.6M in revenue (+15.3% YoY), -$25.3M in net income, and -$23.0M in free cash flow against $18.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CV trading relative to its 50-day, 200-day, and 52-week technical levels?
CV last traded at $6.83 (-1.58% on volume of 86,781 shares), positioning the stock +6.06% above its 50-day simple moving average ($6.44) and +7.39% above its 200-day simple moving average ($6.36). Across its 52-week range of $4.50 to $15.37, CV sits at the 21.4% percentile with a 14-day RSI of 56.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.6% ($6.24 to $7.42).
CV Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CV stock moving today?
Why CV Stock slipped -1.58% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 45/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
CV — CapsoVision Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:37:37Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, CapsoVision Inc. scores 45 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The Fundamental Cash Engine pillar scores 8 out of 20, reflecting ROIC of -35% and an FCF yield of -6.22%, which signals that the business is currently consuming rather than generating cash relative to its market value. The Whale 13F Flow pillar scores 10 out of 20, indicating institutional accumulation and options positioning that are only moderately supportive. The Insider Conviction pillar scores 3 out of 20, the weakest reading in the rating, reflecting the SEC Form 4 and Congressional PTR cluster flow in the source data. The Macro Regime Fit pillar scores 10 out of 20, with a beta of 1.0 and sector sensitivity that offers no clear defensive cushion. The Forensic Balance Sheet pillar scores 14 out of 20, supported by an Altman Z-Score of 26, a Piotroski F-Score of 4 out of 9, and a Debt/Equity ratio of 0.5.
For a prospective investor evaluating the stock today, the upside case rests on the balance sheet and institutional flow rather than on operating cash generation, since the operating and net margins of -60% and the negative FCF are the dominant facts. Any valuation discussion is constrained because P/E, Forward P/E, EV/EBITDA, and EPS are not available in source data, so the price of $6.94 cannot be tested against earnings. The stock's 52-week range of $4.5 to $15.37 shows a large drawdown from the high, which the Wyckoff Distribution headline in the news feed characterizes as distribution. The second-order implication is that the rating's weakest links, insider conviction and cash generation, are the signals most likely to determine whether the balance-sheet strength can be converted into shareholder value. This analysis is educational and is not personalized financial advice.
Business
CapsoVision Inc. (CV) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. Per the profile, the company carries a market capitalization of $0.4B. Per the recent news feed, the company's capsule platform targets cancer screening. The source data does not describe its customer base or detailed revenue model; the reported gross margin of 52.9% and revenue of $13.6M for FY 2025 are the only commercial indicators available.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $13.6M | $-25.5M | $-25.3M | N/A | $-23.0M | N/A | N/A |
| FY 2024 | $11.8M | $-19.9M | $-19.9M | N/A | $-20.2M | N/A | N/A |
Per the SEC financials, revenue rose from $11.8M in FY 2024 to $13.6M in FY 2025, while operating losses widened from $-19.9M to $-25.5M. Per the market data, the operating margin and net margin are both -60% and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 4 out of 9, with a Debt/Equity ratio of 0.5. Cash and debt balances are not available in source data for either period.
Recent Catalysts & News Wire Analysis
- Earnings event: A headline states CapsoVision will release Third Quarter 2026 Financial Results on November 12, 2026, with a live webcast covering results and a corporate update that same day.
- Conference presence: The company is slated to present at the 20th Annual LD Micro Main Event.
- Technical flag: A news item describes the stock edging higher to $6.53 with buyers testing the upper range, framed as Wyckoff Distribution. This is a risk watch item given the rating's distribution warning.
- Product narrative: A news item characterizes the capsule platform as targeting cancer screening.
- Source quality: All six headlines carry a YELLOW light and MARKET WIRE impact label, and one item's source field is a URL rather than a named publication.
- Butterfly Supply-Chain Graph: Supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Open Questions
- What are the cash and debt balances, which are listed as N/A in both reported periods, and how long does current cash cover the $-23.0M FY 2025 free cash flow burn?
- What are the EPS, P/E, and EV/EBITDA figures that would allow the $6.94 price to be tested against earnings?
- Which upstream suppliers, manufacturers, or regulatory milestones does the capsule platform depend on?
- What do the November 12, 2026 third-quarter results show about the revenue trajectory against the widening operating losses?
- Who are the institutional holders and insiders behind the Whale 13F and Insider Conviction readings, given that the holders section is empty?
CV Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for CapsoVision Inc. (CV) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 13h ago
CapsoVision, Inc. Estimates – NASDAQ:CV TradingView report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 16h ago
CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026 Yahoo Finance report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 19h ago
A live webcast will cover CapsoVision's results and corporate update on Nov. 12. Stock Titan report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 22h ago
CapsoVision to Present at the 20th Annual LD Micro Main Event Yahoo Finance report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
CapsoVision Inc. (CV) Edges Higher to $6.53 as Buyers Test Upper Range - Wyckoff Distribution https://www.siam.in/ report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com UK • 1d ago
CapsoVision at ld micro main event: capsule platform targets cancer screening Investing.com UK report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago
CapsoVision Inc. (CV) Holds Near $6.68 as Traders Eye $7.01 Resistance - Box Spread https://www.dars.gov.et/ report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.siam.in/ • 1d ago
CapsoVision (CV) Climbs 6.73% to $6.58 as Buyers Push Toward Key Resistance - Growth Factor https://www.siam.in/ report covering CapsoVision Inc. (CV) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CV Bull vs. Bear Conversation Board — What's Your Call at $6.83?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CV 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $6.11 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is CV (D • RQD 45/100) a Buy at $6.94?
Welcome to the CV (CapsoVision Inc.) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Electromedical & Electrotherapeutic Apparatus. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $5.34 (-23.1%)
Spot @ $6.94 Pump the brakes on CV — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on CV, but look at what you are paying: current EV/EBITDA multiples with 52.9% gross margins. Unless CapsoVision Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH
🎯 Target: $8.05 (+16.0%)
Spot @ $6.94 CV cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on CV, the market is fixating on short-term headline noise in Biotechnology: Electromedical & Electrotherapeutic Apparatus and ignoring the balance sheet and cash flow trajectory. At $6.94 (52-wk range $4.50 - $15.37), any beat on forward guidance forces shorts and underweight funds to chase.